Arbutus Biopharma (NASDAQ:ABUS – Get Rating) had its price target lifted by HC Wainwright from $8.00 to $8.50 in a report published on Monday morning, The Fly reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. ABUS has been the topic of a number of other reports. Chardan Capital raised their […]
Arbutus Biopharma Co. (NASDAQ:ABUS – Get Rating) has earned an average recommendation of “Buy” from the seven analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average twelve-month target […]
Zacks Investment Research lowered shares of Arbutus Biopharma (NASDAQ:ABUS – Get Rating) from a buy rating to a hold rating in a report issued on Friday, Zacks.com reports. According to Zacks, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B […]